Moberg Pharma Logo

Moberg Pharma

Develops & commercializes a leading topical treatment for nail fungus for European markets.

MOB | ST

Overview

Corporate Details

ISIN(s):
SE0011311596 (+3 more)
LEI:
549300XFXK7DVGDRP410
Country:
Sweden
Address:
Gustavslundsvagen 42, 167 51 Stockholm
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Moberg Pharma is a Swedish pharmaceutical company focused on the development and commercialization of proprietary medical innovations. The company's primary asset is MOB-015, a novel topical treatment for onychomycosis (nail fungus). Marketed as Terclara®, this over-the-counter terbinafine-based product has demonstrated high fungal cure rates in Phase 3 clinical trials. Moberg Pharma has gained market approval in 13 European countries and has established Terclara® as a market leader in Sweden and Norway. The company's strategic goal is to position MOB-015 as the world's leading treatment for nail fungus, addressing a large patient population globally.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-07 08:11
ISS
English 10.8 KB
2025-09-29 14:04
Post-Annual General Meeting Information
Bulletin from Moberg Pharma’s Extraordinary General Meeting held on 29 Septembe…
English 175.9 KB
2025-09-29 14:04
Post-Annual General Meeting Information
Kommuniké från extra bolagsstämma i Moberg Pharma den 29 september 2025
Swedish 200.1 KB
2025-09-03 08:00
Pre-Annual General Meeting Information
Notice of extraordinary general meeting in Moberg Pharma AB (publ)
English 181.0 KB
2025-09-03 08:00
Pre-Annual General Meeting Information
Kallelse till extra bolagsstämma i Moberg Pharma AB (publ)
Swedish 155.9 KB
2025-08-12 08:00
Interim Report
Swedish 645.6 KB
2025-08-12 08:00
Interim Report
English 674.6 KB
2025-07-03 16:30
Major Shareholding Notification
Swedish 10.1 KB
2025-07-03 10:32
Major Shareholding Notification
Swedish 10.9 KB
2025-06-30 08:00
Declaration of Voting Results & Voting Rights Announcements
Ändring av antalet aktier och röster i Moberg Pharma AB (publ)
Swedish 155.9 KB
2025-06-30 08:00
Declaration of Voting Results & Voting Rights Announcements
New number of shares and votes in Moberg Pharma AB (publ)
English 156.8 KB
2025-06-25 08:00
Board/Management Information
Changes to Moberg Pharma´s Management
English 157.4 KB
2025-06-25 08:00
Board/Management Information
Förändringar i Moberg Pharmas ledningsgrupp
Swedish 157.5 KB
2025-06-18 10:43
Major Shareholding Notification
Swedish 10.5 KB
2025-06-16 08:00
Earnings Release
Terclara market leader also in Norway
English 132.8 KB

Automate Your Workflow. Get a real-time feed of all Moberg Pharma filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Moberg Pharma via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2021-11-11 Mark Beveridge Other Buy 3,000 17,730.00 SEK
2021-11-10 Mark Beveridge Other Buy 3,000 17,310.00 SEK
2021-11-09 Mark Beveridge Other Buy 5,000 29,800.00 SEK
2021-02-10 Cindy Wong Other Buy 5,000 31,675.00 SEK
2021-02-09 Cindy Wong Other Buy 5,000 30,800.00 SEK

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden ABLI
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America 950130
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI

Talk to a Data Expert

Have a question? We'll get back to you promptly.